- Home
- ERAS
ERAS
Erasca Inc.
as 11-15-2024 4:00pm EST
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 719.0M | IPO Year: | 2021 |
| Target Price: | $6.10 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.51 - $3.45 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Erasca Inc. News
ERAS Breaking Stock News: Dive into ERAS Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GlobeNewswire
5 days ago
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
GlobeNewswire
12 days ago
Erasca to Present at Upcoming Investor Conferences
Simply Wall St.
18 days ago
Erasca Insiders Added US$1.95m Of Stock To Their Holdings
GlobeNewswire
24 days ago
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
GlobeNewswire
2 months ago
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Simply Wall St.
2 months ago
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company
GlobeNewswire
3 months ago
Erasca to Present at Upcoming Investor Conferences in September
Compare ERAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ERAS Erasca Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.